Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
8,311 INR | -0.74% | -4.15% | +3.10% |
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Considering the small differences between the analysts' various estimates, the group's business visibility is good.
Weaknesses
- The company's earnings growth outlook lacks momentum and is a weakness.
- With an expected P/E ratio at 32.69 and 30.04 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The valuation of the company is particularly high given the cash flows generated by its activity.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+3.10% | 2.31B | - | ||
+20.66% | 43.57B | B- | ||
+20.38% | 22.7B | B+ | ||
+11.68% | 14.32B | - | ||
+11.48% | 13.42B | B+ | ||
+43.41% | 11.83B | B | ||
-9.28% | 6.98B | B+ | ||
-0.05% | 6.79B | - | - | |
-8.87% | 5.73B | - | - | |
+12.33% | 5.51B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
- Stock Market
- Equities
- SANOFI Stock
- SANOFI Stock
- Ratings Sanofi India Limited